Pipeline

Pipeline

Artizan’s ability to identify, characterize and inhibit microbial virulence factors is applicable to a range of therapeutic areas, including gastrointestinal diseases, central nervous system conditions, certain cancers, metabolic disorders and liver disease.

Our lead program is for treatment of inflammatory bowel disease (IBD), which is comprised of Crohn’s Disease and ulcerative colitis. IBD is a complex condition for which currently available therapies fail to address the root cause of disease. Artizan is developing novel small molecules and antibodies that neutralize the offending pathogen’s ability to initiate an inflammatory cascade.